L
LSL Pharma Group Inc
XTSX:LSL
LSL Pharma Group Inc
XTSX:LSL
Price:
0.395
CAD
Market Closed
Market Cap:
CA$50.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
O
|
Oesterreichische Post AG
XHAM:O3P
|
AT |
|
HC Group Inc
OTC:HCINF
|
CN |
|
Infragreen Group Ltd
ASX:IFN
|
AU |
LSL Pharma Group Inc
Research & Development
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
LSL Pharma Group Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
LSL Pharma Group Inc
XTSX:LSL
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Research & Development
-$629m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Research & Development
-$300.9m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-35%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Research & Development
-CA$27.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-26%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Research & Development
-$21k
|
CAGR 3-Years
33%
|
CAGR 5-Years
31%
|
CAGR 10-Years
35%
|
|
No Stocks Found
LSL Pharma Group Inc
Glance View
LSL Pharma Group, Inc. operates as a pharmaceutical company. The company is headquartered in Boucherville, Quebec. The company went IPO on 2011-03-08. The firm specializes in the development, manufacturing, and distribution of natural health products and dietary supplements in solid dosage forms. The firm is also engaged in selling sterile ophthalmic pharmaceutical products.
LSL
Intrinsic Value
0.446
CAD
Undervaluation 11%
L
